Clinical bottom line
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary small vessel disease characterized by progressive cognitive decline and motor impairment. Early intervention strategies targeting vascular risk factors and symptomatic management may modestly delay progression of cognitive and motor symptoms, but no disease-modifying therapies currently exist. Evidence supporting specific early interventions remains limited and largely observational, underscoring the need for cautious interpretation and individualized clinical decision-making.
What the evidence shows
CADASIL is caused by NOTCH3 gene mutations leading to small vessel pathology, subcortical infarcts, and white matter changes, manifesting clinically as migraine with aura, recurrent strokes, cognitive impairment, and motor dysfunction (Rajalakshmi et al., 2015; Luu et al., 2022). Cognitive symptoms often begin with executive dysfunction and progress to subcortical dementia, while motor symptoms include gait disturbances and parkinsonism features (Farah et al., 2025).
Current evidence on early intervention strategies in CADASIL primarily focuses on aggressive management of vascular risk factors such as hypertension, smoking cessation, and lipid control, extrapolated from small vessel disease literature. Observational data suggest that controlling these factors may reduce incident lacunes and delay symptom progression (De Guio et al., 2017). However, no randomized controlled trials have definitively demonstrated efficacy of early vascular risk management specifically in CADASIL populations.
Symptomatic treatments, including antiplatelet agents, are commonly used to reduce stroke risk, though their benefit in CADASIL remains uncertain given the disease’s unique pathophysiology (Bickle et al., 2021). Cognitive rehabilitation and physical therapy have been proposed to address executive dysfunction and motor impairment, but evidence is anecdotal or derived from broader small vessel disease cohorts rather than CADASIL-specific trials (Tahat et al., 2021).
Neuroimaging studies highlight that incident lacunes and white matter changes correlate with clinical deterioration, supporting the rationale for early detection and intervention (De Guio et al., 2017). However, the heterogeneity in clinical presentation and progression complicates standardized early intervention protocols.
Caveats and uncertainty
The rarity and genetic nature of CADASIL limit large-scale clinical trials, resulting in a paucity of high-quality evidence for early intervention efficacy. Most data derive from case series, observational cohorts, or extrapolation from sporadic small vessel disease, which may not fully capture CADASIL’s distinct pathophysiology (Rajalakshmi et al., 2015; Farah et al., 2025).
The impact of antiplatelet therapy and other vascular risk modifications on long-term cognitive and motor outcomes in CADASIL remains unclear, with potential risks of hemorrhage needing consideration. Cognitive rehabilitation and physical therapy approaches lack rigorous evaluation in this population, making their benefit speculative.
Genetic counseling and early diagnosis may facilitate risk factor management but do not currently alter disease trajectory. Emerging biomarkers and imaging techniques may improve early detection but require validation.
How this may change practice
Clinicians managing patients with CADASIL should prioritize early diagnosis through genetic testing and neuroimaging to identify at-risk individuals. Early and aggressive management of vascular risk factors remains a cornerstone, despite limited direct evidence, given the plausible benefit and low risk.
Symptomatic treatment tailored to cognitive and motor symptoms should be individualized, incorporating multidisciplinary rehabilitation approaches where feasible. Clinicians should counsel patients and families regarding the current lack of disease-modifying therapies and the importance of supportive care.
Ongoing research into targeted therapies and biomarkers may in future refine early intervention strategies. Until then, clinical vigilance and personalized management remain essential.